{"id":3118,"date":"2025-09-12T03:05:34","date_gmt":"2025-09-12T03:05:34","guid":{"rendered":"https:\/\/medicine.nus.edu.sg\/medphc\/?p=3118"},"modified":"2025-09-12T03:05:44","modified_gmt":"2025-09-12T03:05:44","slug":"apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia","status":"publish","type":"post","link":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/","title":{"rendered":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia"},"content":{"rendered":"

\"\"<\/p>\n

\n
\n

Abstract<\/h2>\n
\n

Acute myeloid leukaemia (AML) remains a challenging haematological malignancy, with most patients developing resistance to standard-of-care (SOC) treatments. This resistance is often attributed to the overexpression of anti-apoptotic BCL-2 family proteins, which regulate the intrinsic apoptotic pathway by inhibiting pro-apoptotic effector proteins such as BAX and BAK. AML cells exploit this imbalance to evade apoptosis and sustain survival, necessitating the development of novel therapeutic strategies. BH3 mimetics are small-molecule inhibitors targeting the pro-survival BCL-2 family proteins and have emerged as promising agents in patients with AML who are unable to receive high-intensity induction chemotherapy. Co-treatment with the BCL-2-specific inhibitor venetoclax and various SOC therapies has been proven effective, with several combinations now approved by the\u00a0US Food and Drug Administration for adults with AML who are \u226575\u2009years of age and\/or are ineligible for intensive induction chemotherapy, on the\u00a0basis of improved response rates and survival outcomes compared with the previous SOC. In this Review, we highlight the transformative potential of BH3 mimetics in AML therapy, including ongoing studies investigating novel combination regimens and efforts to further refine treatment strategies, with the ultimate goal of improving outcomes for patients with AML.<\/p>\n<\/div>\n

Full Article:\u00a0https:\/\/www.nature.com\/articles\/s41571-025-01068-0<\/a><\/p>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Abstract Acute myeloid leukaemia (AML) remains a challenging haematological malignancy, with most patients developing resistance to standard-of-care (SOC) treatments. This resistance is often attributed to the overexpression of anti-apoptotic BCL-2 family proteins, which regulate the intrinsic apoptotic pathway by inhibiting pro-apoptotic effector proteins such as BAX and BAK. AML cells exploit this imbalance to evade […]<\/p>\n","protected":false},"author":9345,"featured_media":3119,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-3118","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"acf":[],"yoast_head":"\nApoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology\" \/>\n<meta property=\"og:description\" content=\"Abstract Acute myeloid leukaemia (AML) remains a challenging haematological malignancy, with most patients developing resistance to standard-of-care (SOC) treatments. This resistance is often attributed to the overexpression of anti-apoptotic BCL-2 family proteins, which regulate the intrinsic apoptotic pathway by inhibiting pro-apoptotic effector proteins such as BAX and BAK. AML cells exploit this imbalance to evade […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharmacology\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-12T03:05:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-12T03:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Woon Fei\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Woon Fei\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/\"},\"author\":{\"name\":\"Woon Fei\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/person\\\/ea3ccd10ab2f2bba51fd804396287cb0\"},\"headline\":\"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia\",\"datePublished\":\"2025-09-12T03:05:34+00:00\",\"dateModified\":\"2025-09-12T03:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/\"},\"wordCount\":215,\"publisher\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2025\\\/09\\\/20250901-APK.jpg\",\"articleSection\":[\"Publications\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/\",\"name\":\"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2025\\\/09\\\/20250901-APK.jpg\",\"datePublished\":\"2025-09-12T03:05:34+00:00\",\"dateModified\":\"2025-09-12T03:05:44+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/publications\\\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2025\\\/09\\\/20250901-APK.jpg\",\"contentUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2025\\\/09\\\/20250901-APK.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#website\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/\",\"name\":\"Pharmacology\",\"description\":\"Just another WordPress site\",\"publisher\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#organization\",\"name\":\"Pharmacology\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2022\\\/06\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/wp-content\\\/uploads\\\/sites\\\/33\\\/2022\\\/06\\\/logo.png\",\"width\":467,\"height\":69,\"caption\":\"Pharmacology\"},\"image\":{\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/medicine.nus.edu.sg\\\/medphc\\\/#\\\/schema\\\/person\\\/ea3ccd10ab2f2bba51fd804396287cb0\",\"name\":\"Woon Fei\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g\",\"caption\":\"Woon Fei\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/","og_locale":"en_US","og_type":"article","og_title":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology","og_description":"Abstract Acute myeloid leukaemia (AML) remains a challenging haematological malignancy, with most patients developing resistance to standard-of-care (SOC) treatments. This resistance is often attributed to the overexpression of anti-apoptotic BCL-2 family proteins, which regulate the intrinsic apoptotic pathway by inhibiting pro-apoptotic effector proteins such as BAX and BAK. AML cells exploit this imbalance to evade […]","og_url":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/","og_site_name":"Pharmacology","article_published_time":"2025-09-12T03:05:34+00:00","article_modified_time":"2025-09-12T03:05:44+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg","type":"image\/jpeg"}],"author":"Woon Fei","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Woon Fei","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/#article","isPartOf":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/"},"author":{"name":"Woon Fei","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/person\/ea3ccd10ab2f2bba51fd804396287cb0"},"headline":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia","datePublished":"2025-09-12T03:05:34+00:00","dateModified":"2025-09-12T03:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/"},"wordCount":215,"publisher":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg","articleSection":["Publications"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/","url":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/","name":"Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemia - Pharmacology","isPartOf":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#website"},"primaryImageOfPage":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/#primaryimage"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/#primaryimage"},"thumbnailUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg","datePublished":"2025-09-12T03:05:34+00:00","dateModified":"2025-09-12T03:05:44+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/publications\/apoptosis-targeting-bh3-mimetics-transforming-treatment-for-patients-with-acute-myeloid-leukaemia\/#primaryimage","url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg","contentUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2025\/09\/20250901-APK.jpg","width":1280,"height":720},{"@type":"WebSite","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#website","url":"https:\/\/medicine.nus.edu.sg\/medphc\/","name":"Pharmacology","description":"Just another WordPress site","publisher":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medicine.nus.edu.sg\/medphc\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#organization","name":"Pharmacology","url":"https:\/\/medicine.nus.edu.sg\/medphc\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/logo\/image\/","url":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2022\/06\/logo.png","contentUrl":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-content\/uploads\/sites\/33\/2022\/06\/logo.png","width":467,"height":69,"caption":"Pharmacology"},"image":{"@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/medicine.nus.edu.sg\/medphc\/#\/schema\/person\/ea3ccd10ab2f2bba51fd804396287cb0","name":"Woon Fei","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fd821aa4493bddccb2a18a5acbef6f52322488bae5bf51dc8d7ea216d7fe4c8c?s=96&d=mm&r=g","caption":"Woon Fei"}}]}},"_links":{"self":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/3118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/users\/9345"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/comments?post=3118"}],"version-history":[{"count":1,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/3118\/revisions"}],"predecessor-version":[{"id":3120,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/posts\/3118\/revisions\/3120"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/media\/3119"}],"wp:attachment":[{"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/media?parent=3118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/categories?post=3118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicine.nus.edu.sg\/medphc\/wp-json\/wp\/v2\/tags?post=3118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}